These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 21054456)
1. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. Kast RE J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456 [TBL] [Abstract][Full Text] [Related]
2. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist. AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462 [No Abstract] [Full Text] [Related]
3. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions. Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908 [TBL] [Abstract][Full Text] [Related]
4. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. MacArthur RD; Novak RM Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888 [TBL] [Abstract][Full Text] [Related]
5. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. Emmelkamp JM; Rockstroh JK Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722 [TBL] [Abstract][Full Text] [Related]
6. Maraviroc: a new CCR5 antagonist. Sayana S; Khanlou H Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053 [TBL] [Abstract][Full Text] [Related]
7. FDA panel backs HIV drug. AIDS Read; 2007 Jun; 17(6):294. PubMed ID: 17632933 [No Abstract] [Full Text] [Related]
8. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Hunt JS; Romanelli F Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948 [TBL] [Abstract][Full Text] [Related]
9. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"]. Zorn F MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590 [No Abstract] [Full Text] [Related]
10. FDA approval: maraviroc. Sax PE AIDS Clin Care; 2007 Sep; 19(9):75. PubMed ID: 18398993 [No Abstract] [Full Text] [Related]
11. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. Bredeek UF; Harbour MJ Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724 [TBL] [Abstract][Full Text] [Related]
12. FDA approves maraviroc tablets. AIDS Patient Care STDS; 2007 Sep; 21(9):702. PubMed ID: 17919097 [No Abstract] [Full Text] [Related]
13. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825 [TBL] [Abstract][Full Text] [Related]
14. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317 [TBL] [Abstract][Full Text] [Related]
15. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008. Yang H; Rotstein DM Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619 [TBL] [Abstract][Full Text] [Related]
16. Something new under the sun. Maraviroc poised for approval. Huff B GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160 [No Abstract] [Full Text] [Related]
17. Maraviroc--new HIV drug. Emerging options need to be used wisely. Vázquez E Posit Aware; 2007; 18(4):18-9. PubMed ID: 17682275 [No Abstract] [Full Text] [Related]
18. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1. Ndegwa S Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399 [TBL] [Abstract][Full Text] [Related]
19. HIV entry inhibitors: progress in development and application. Lai WH; Huang L; Chen CH Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414 [TBL] [Abstract][Full Text] [Related]
20. CCR5 antagonist blocks metastasis of basal breast cancer cells. Velasco-Velázquez M; Jiao X; De La Fuente M; Pestell TG; Ertel A; Lisanti MP; Pestell RG Cancer Res; 2012 Aug; 72(15):3839-50. PubMed ID: 22637726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]